# Poolbeg Pharma plc

## Interim Results for the six months to 30 June 2026

*Strong operational progress as TOPICAL trial builds momentum*

29 September 2026 - **Poolbeg Pharma** (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces its unaudited interim results for the six months to 30 June 2026.

**Highlights & Updates**

- TOPICAL trial initiated following MHRA Clinical Trial Authorisation ("CTA"), with eight of c.30 participants dosed to date. Recruitment activity remains encouraging, with strong engagement from investigators, participating centres and patients.
- Strong financial position maintained, with cash balance of £4.8 million as at 30 June 2026, further strengthened post period end by a fundraise of £3.5 million (before expenses) completed in July 2026. This funds both the POLB 001 TOPICAL trial and the oral GLP-1 proof-of-concept trial through to completion and extends the cash runway into Q2 2028.
- Positive FDA pre-IND meeting, with alignment on POLB 001's development pathway and future Phase 3 primary endpoint.
- Preclinical data presented at the European Hematology Association ("EHA") 2026 Congress supporting POLB 001 as a potential preventative therapy for cancer immunotherapy-induced Cytokine Release Syndrome ("CRS"), together with a poster from The University of Manchester indicating POLB 001's potential to enhance the efficacy of azacitidine in aged models of acute myeloid leukaemia.
- Independent US payer research, covering payers representing c.75 million lives, found willingness to pay at commercially meaningful price points, supporting multi-billion-dollar US peak sales potential for POLB 001.
- Results of the LPS challenge study were published in full in Frontiers in Immunology, a leading peer-reviewed journal. Study demonstrated potent p38 MAPK inhibition, safety and tolerability of POLB 001 and positive impact on a range of key inflammatory biomarkers.
- Global intellectual property portfolio strengthened, including the first patent grants within Poolbeg's cancer immunotherapy-induced CRS patent family, now granted in Canada, Australia and Europe and allowed in Israel.
- Strengthened Scientific Advisory Board with the appointment of oncology and cell therapy expert Dr Adrian Kilcoyne.
- Post period, the TOPICAL trial was recommended to continue as planned following a positive review of the six-patient interim safety cohort, with no changes required to the study protocol.

**Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, said:**
*"The first half of 2026 saw POLB 001 progress from TOPICAL trial preparation into execution, and we have built on that momentum since the period end. Eight patients have now been dosed in the TOPICAL trial and, following a positive review of data from the interim safety cohort, the study will continue as planned.*

*"POLB 001 has the potential to be the first approved preventative therapy for cancer immunotherapy-induced CRS. Positive FDA pre-IND feedback, a growing patent estate and independent US payer research all support its partnering potential.*

*"With both clinical programmes funded through to completion, we believe Poolbeg is well positioned for its next phase of value creation."*

**Enquiries**

**Poolbeg Pharma Plc** +44 (0) 207 183 1499
Jeremy Skillington, CEO ir@poolbegpharma.com
Ian O'Connell, CFO

**Cavendish Capital Markets Ltd (NOMAD & Joint Broker)** +44 (0) 207 220 0500
Geoff Nash, Andrea Callaghan, Trisyia Jamaludin (Corporate Finance)
Nigel Birks (Life Science Specialist Sales)
Harriet Ward (ECM)

**Shore Capital Stockbrokers Ltd (Joint Broker)** +44 (0) 207 408 4090
David Coaten, Harry Davies-Ball (Corporate Advisory)
Malachy McEntyre (Corporate Broking)

**Oak Securities (Joint Broker)** +44 (0) 20 3973 3678
Jerry Keen, Henry Poole

**J&E Davy (Joint Broker)** +353 (0) 1 679 6363
Anthony Farrell, Niall Gilchrist

**Optimum Strategic Communications** +44 (0) 208 078 4357
Nick Bastin, Katie Flint, Henry Adams poolbeg@optimumcomms.com




**About Poolbeg Pharma plc**

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs.

Stay updated: Website | Sign up for RNS alerts | Presentation | X | LinkedIn

**Forward-Looking Statements**

This announcement may contain forward-looking statements and the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and

consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information.

**CEO Statement**

The first half of 2026 marked a significant period of progress for Poolbeg as we successfully advanced POLB 001 through a series of regulatory, operational and commercial milestones.

POLB 001 is being developed as a potential first approved preventative therapy for cancer immunotherapy-induced Cytokine Release Syndrome ("CRS"). We believe POLB 001 has the potential to address a significant unmet medical need and support broader access to certain cancer immunotherapies by reducing the incidence of CRS, a serious and potentially life-threatening side effect that can limit treatment availability and increase healthcare burden.

During the period, we strengthened the programme on multiple fronts. We secured MHRA Clinical Trial Authorisation for the TOPICAL trial and were delighted to have leading sites from across the UK participating. In parallel, a positive pre-IND meeting with the FDA provided greater clarity on the US development pathway for POLB 001, supporting our ongoing partnering discussions.

Independent US payer research conducted by Acumetis, reconfirmed the significant market opportunity for POLB 001 and reinforced its value proposition to healthcare systems and potential partners.

In addition, we have continued to build our global intellectual property portfolio, including securing the first national grant within our cancer immunotherapy-induced CRS patent family, an important milestone that further strengthens the protection of our IP and the future value of POLB 001.

Finally, we expanded our scientific expertise through the appointment of Dr Adrian Kilcoyne, a cancer immunotherapy and CRS expert, to our Scientific Advisory Board.

Together, these achievements have strengthened the POLB 001 package and provide a strong platform as the TOPICAL trial progresses. With growing regulatory, commercial and scientific validation behind the programme, we believe POLB 001 is well positioned to realise its potential as a novel preventative therapy for CRS and to create value through future partnering opportunities.

**POLB 001**

POLB 001, the Company's lead strategic programme, delivered key clinical, regulatory and operational milestones during H1 2026, further supporting its development as a potential preventative therapy for cancer immunotherapy-induced CRS.

*POLB 001 TOPICAL Clinical Trial*

The TOPICAL trial is evaluating POLB 001 in c.30 relapsed/refractory multiple myeloma patients receiving the approved bispecific antibody teclistamab, provided by Johnson & Johnson at no cost to the Company, across six leading specialist cancer centres in the UK. The trial has been designed to generate rapid clinical data given the acute nature of CRS.

During the period, we successfully progressed the programme from regulatory approval into active clinical execution, following site activation and patient recruitment.

Post-period, in July 2026, the Company announced the dosing of the first patient in the TOPICAL clinical trial, marking the commencement of active patient treatment.

Most recently, the review of data from the six-patient safety cohort was completed, resulting in a recommendation that the trial continue as planned, with no changes required to the study protocol. With eight patients now dosed, this positive review represents an important milestone for the TOPICAL trial. Recruitment is continuing across leading UK clinical sites, with further patients expected to be enrolled and additional sites activated. We are pleased with the rate of recruitment to date and encouraged by interest from additional clinical sites in participating in the study.

*Intellectual Property*

We have continued to strengthen the POLB 001 intellectual property estate. During the period, we secured the first patent grant within our cancer immunotherapy-induced CRS patent family from IP Australia, followed by a patent grant in Canada and a decision to grant from the European Patent Office. We also received a decision to grant our Immunomodulator II patent in South Africa, providing protection for POLB 001 for the prevention of hypercytokinaemia and severe influenza until December 2038.

Post-period end, we received a Notice of Allowance in Israel, indicating a further national patent within the CRS family is set to be granted.

Collectively, these awards enhance the long-term value of POLB 001 and support our ongoing business development and partnering activities.

*Regulatory & Partnering*

We continued to strengthen the regulatory and commercial positioning of POLB 001 during the period. In May 2026, we announced a positive outcome from a pre-Investigational New Drug ("pre-IND") meeting with the U.S. Food and Drug Administration ("FDA"). The FDA feedback was broadly aligned with key aspects of our envisioned development pathway for POLB 001, including alignment on the proposed primary endpoint for a future Phase 3 clinical trial. This important milestone provides greater clarity regarding the anticipated US development pathway, further de-risks the programme and provides potential partners with a higher degree of certainty regarding the route to market. We believe this feedback reaffirms the attractiveness of POLB 001 and supports our ongoing partnering discussions.

In April 2026, we reported findings from independent US payer research conducted by Acumetis, which engaged payers covering approximately 75 million lives across commercial insurance providers, Medicare and Medicaid. The research reconfirmed the significant unmet need and cost burden associated with cancer immunotherapy-induced CRS, and highlighted POLB 001's potential to reduce hospital costs and enable a meaningful shift in care from specialist centres towards outpatient and community settings. Importantly, payers indicated a willingness to pay at commercially meaningful price points, supporting multi-billion-dollar US peak sales potential and reinforcing the programme's appeal to potential partners.

We remain actively engaged with potential partners in respect of POLB 001 and believe that the recent positive review of the interim safety cohort data could further enhance commercial interest and support ongoing partnering discussions.

**Oral GLP-1 Programme**

We continue to advance our oral encapsulated GLP-1 programme, which combines AnaBio Technologies' proprietary oral microencapsulation technology with a GLP-1 receptor agonist. The programme is designed to address one of the largest and fastest-growing therapeutic markets globally through a differentiated oral delivery approach.

During the period, we continued preparations for the proof-of-concept clinical study, which is expected to commence in H2 2026. We believe successful clinical validation could create substantial value and unlock multiple opportunities within obesity and broader metabolic disease indications.

**Financial**

Poolbeg ended the period with a cash balance of £4.8 million (H1 2025: £10.0 million). The loss for the period amounted to £1.9 million (H1 2025: £2.2 million), comprising R&D expenses of £0.9 million (H1 2025: £0.5 million), administrative expenses £1.3 million (H1 2025: £2.0 million), offset by tax rebates and other income & charges of £0.3 million (H1 2025: £0.4 million).

Following the successful £3.5 million (before expenses) fundraising completed in July 2026, we strengthened our balance sheet and extended our cash runway into Q2 2028. The fundraising was supported by both existing and new investors and included a further £250,000 subscription from our Executive Chair, Cathal Friel, demonstrating his continued confidence in Poolbeg's strategy and future prospects. The net proceeds are expected to strengthen

Poolbeg's position in ongoing partnering discussions while funding both the POLB 001 TOPICAL trial and the Oral GLP-1 proof-of-concept trial through to completion.

**Outlook**

Bispecific antibodies are playing an increasingly important role in cancer treatment, and we believe the case for an effective CRS preventative therapy continues to strengthen. POLB 001 has the potential to be the first approved preventative therapy for cancer immunotherapy-induced CRS, reducing healthcare system burden, improving patient outcomes and expanding access to life-saving cancer treatments beyond specialist centres and into outpatient and community settings.

Following the positive review of data from the interim safety cohort, our focus is on continued recruitment in the TOPICAL trial, with further clinical sites having expressed interest in joining. We continue to build a comprehensive evidence package across the programme, designed to support partnering discussions.

Alongside POLB 001, we are advancing preparations for the oral encapsulated GLP-1 proof-of-concept study, expected to commence in H2 2026. We believe the programme offers a differentiated opportunity in one of the largest pharmaceutical markets globally and could create further value and partnering opportunities following successful clinical validation.

With both clinical programmes funded through to completion, multiple anticipated catalysts and an experienced management team with a proven track record, we believe Poolbeg is entering a pivotal phase. We look forward to delivering further progress as we work to unlock the full value of our portfolio for patients and shareholders.

**Jeremy Skillington**
**CEO**
28 September 2026

**Consolidated Statement of Comprehensive Income**
*For the six months to 30 June 2026*

| | Note | **Unaudited Six months to 30 June 2026 £'000** | Unaudited Six months to 30 June 2025 £'000 | Audited Year ended 31 December 2025 £'000 |
|---|---|---|---|---|
| Revenue | | **—** | — | — |
| Cost of sales | | **—** | — | — |
| **Gross profit** | | **—** | — | — |
| Administrative expenses | | **(1,338)** | (2,031) | (4,893) |
| Other operating income | | **148** | 209 | 422 |
| Research and development expenses | | **(873)** | (527) | (1,525) |
| Impairment of intangible assets | | **—** | — | (26) |
| Net losses on disposal of assets | | **(1)** | — | (5) |
| **Operating loss** | | **(2,064)** | (2,349) | (6,027) |
| Finance income | | **87** | 116 | 253 |
| **Loss before income tax** | | **(1,977)** | (2,233) | (5,774) |
| Taxation | | **37** | 55 | 79 |
| **Loss and total comprehensive loss for the period attributable to the equity holders of the Company** | | **(1,940)** | (2,178) | (5,695) |
| | | | | |
| **Loss per share:** | | | | |
| Loss per share – basic and diluted, attributable to ordinary equity holders of the parent | 3 | **(0.28)p** | (0.43)p | (0.94)p |

**Consolidated Statement of Financial Position**

*As at 30 June 2026*

| | Note | **Unaudited 30 June 2026 £'000** | Unaudited 30 June 2025 £'000 | Audited 31 December 2025 £'000 |
|---|---|---|---|---|
| **Assets** | | | | |
| **Non-current assets** | | | | |
| Intangible assets | 4 | **1,690** | 1,662 | 1,674 |
| **Total non-current assets** | | **1,690** | 1,662 | 1,674 |
| | | | | |
| **Current assets** | | | | |
| Trade and other receivables | 5 | **640** | 738 | 555 |
| Cash and cash equivalents | | **4,819** | 9,961 | 7,713 |
| **Total current assets** | | **5,459** | 10,699 | 8,268 |
| | | | | |
| **Total assets** | | **7,149** | 12,361 | 9,942 |
| | | | | |
| **Equity and liabilities** | | | | |
| **Equity attributable to owners of the parent** | | | | |
| Share capital | | **141** | 139 | 139 |
| Share premium | | **27,538** | 27,548 | 27,538 |
| Other reserves | | **3,409** | 3,166 | 3,362 |
| Accumulated deficit | | **(24,378)** | (18,921) | (22,438) |
| **Total equity** | | **6,710** | 11,932 | 8,601 |
| | | | | |
| **Current liabilities** | | | | |
| Trade and other payables | | **439** | 429 | 1,341 |
| **Total current liabilities** | | **439** | 429 | 1,341 |
| **Total liabilities** | | **439** | 429 | 1,341 |
| | | | | |
| **Total equity and liabilities** | | **7,149** | 12,361 | 9,942 |

**Consolidated Statement of Changes in Equity**
*For the six months to 30 June 2026*

| | Note | Share capital £'000 | Share premium £'000 | Share based payment reserve £'000 | Merger reserve £'000 | Accumulated deficit £'000 | Total £'000 |
|---|---|---|---|---|---|---|---|
| **At 1 January 2025** | | 100 | 23,100 | 1,361 | 1,455 | (16,743) | **9,273** |
| Loss and total comprehensive loss for the period | | — | — | — | — | (2,178) | **(2,178)** |
| Issue of fee shares | | — | 65 | — | — | — | **65** |
| Issue of shares for cash | | 39 | 4,826 | — | — | — | **4,865** |
| Costs charged against share premium | | — | (443) | — | — | — | **(443)** |
| Share based payments | | — | — | 350 | — | — | **350** |
| **Balance at 30 June 2025** | | 139 | 27,548 | 1,711 | 1,455 | (18,921) | **11,932** |
| Loss and total comprehensive loss for the period | | — | — | — | — | (3,517) | **(3,517)** |
| Costs charged against share premium | | — | (10) | — | — | — | **(10)** |
| Share based payments | | — | — | 196 | — | — | **196** |
| **Balance at 31 December 2025** | | 139 | 27,538 | 1,907 | 1,455 | (22,438) | **8,601** |
| Loss and total comprehensive loss for the period | | — | — | — | — | (1,940) | **(1,940)** |
| Issue of shares on exercise of options | 3 | 2 | — | — | — | — | **2** |
| Share based payments | | — | — | 47 | — | — | **47** |
| **Balance at 30 June 2026** | | 141 | 27,538 | 1,954 | 1,455 | (24,378) | **6,710** |

**Consolidated Statement of Cash Flows**
*For the six months to 30 June 2026*

| | Note | **Unaudited Six months to 30 June 2026 £'000** | Unaudited Six months to 30 June 2025 £'000 | Audited Year ended 31 December 2025 £'000 |
|---|---|---|---|---|
| **Cash flows from operating activities** | | | | |
| **Loss on ordinary activities before taxation** | | **(1,977)** | (2,233) | (5,774) |
| Amortisation | 4 | **37** | 26 | 59 |
| Impairment of intangible assets | | **—** | — | 26 |
| Disposal of intangible assets | 4 | **1** | — | 5 |
| Share based payment expense | | **47** | 350 | 546 |
| Finance income | | **(87)** | (116) | (253) |
| R&D tax credits | | **(10)** | — | 74 |
| *Movements in working capital and other adjustments:* | | | | |
| Change in trade and other receivables | 5 | **(38)** | 56 | 189 |
| Change in trade and other payables | | **(902)** | (545) | 367 |
| **Net cash flow used in operating activities** | | **(2,929)** | (2,462) | (4,761) |
| | | | | |
| **Cash flow from investing activities** | | | | |
| Payments for intangible assets | 4 | **(54)** | (4) | (80) |
| Interest received from bank | | **87** | 116 | 253 |
| **Net cash flow from investing activities** | | **33** | 112 | 173 |
| | | | | |
| **Cash flow from financing activities** | | | | |
| Net proceeds from issue of equity instruments | 3 | **2** | 4,487 | 4,477 |
| **Net cash flow from financing activities** | | **2** | 4,487 | 4,477 |
| | | | | |
| **Net change in cash and cash equivalents** | | **(2,894)** | 2,137 | (111) |
| Cash and cash equivalents at beginning of period | | **7,713** | 7,824 | 7,824 |
| **Cash and cash equivalents at end of period** | | **4,819** | 9,961 | 7,713 |

**Notes to the Interim Results**

**1. General information**

Poolbeg Pharma plc ("Poolbeg" or the "Company") is a public company limited by shares incorporated in England and Wales with company number 13279507. The Company is listed on the AIM market of the London Stock Exchange (ticker: POLB.L, ISIN: GB00BKPG7Z60).

Poolbeg is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field.

**2. Basis of preparation**

The Interim Results of the Company for the six months to 30 June 2026 comprise those of the Company and its subsidiaries (together the "Group"). The Interim Results have been prepared on the going concern basis and under the historical cost convention in accordance with the recognition and measurement requirements of United Kingdom adopted International Accounting Standards ("IFRS") and their interpretations issued by the International Accounting Standards Board ("IASB"), and in accordance with those parts of the Companies Act 2006 applicable to companies reporting under IFRS. As is permitted by the AIM rules, the Directors have not adopted the requirements of IAS 34 "Interim Financial Reporting" in preparing the financial statements. Accordingly, the financial statements are not in full compliance with IFRS and have neither been audited nor reviewed pursuant to guidance issued by the Auditing Practices Board.

The financial information for the six months to 30 June 2026 and 30 June 2025 is unaudited. The information for the year ended 31 December 2025 has been extracted from the Company's audited accounts on which the auditors issued an unqualified audit opinion. The information presented for that period does not constitute full accounts for that period. The 31 December 2025 audited accounts have been delivered to Companies House.

The financial information is presented in pounds sterling ("£") which is the functional and presentation currency of the Company. Balances are rounded to the nearest thousand (£'000) except where otherwise indicated.

The Interim Results were approved by the Board of Directors on [28] September 2026.

The accounting policies used in the preparation of the Interim Results are consistent with those used in the Company's audited financial statements for the year ended 31 December 2025.

**3. Loss per share – basic and diluted**

The Group presents basic and diluted loss per share ("LPS") data for its ordinary shares. Basic LPS is calculated by dividing the loss attributable to ordinary shareholders of the Company by the weighted average number of ordinary shares outstanding during the period. Diluted LPS is determined by adjusting the loss attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding for the effects of all dilutive potential ordinary shares, which comprise warrants and share options granted by the Company.

***Issued share capital – ordinary shares of 0.02p each***

| Share Issue Details | Number of shares | Weighted average shares |
|---|---|---|
| 31 December 2024 | 500,000,000 | |
| 25 June 2025 - share placing & fee shares | 197,200,000 | |
| **30 June 2025** | **697,200,000** | **506,537,017** |
| **31 December 2025** | **697,200,000** | **602,652,055** |
| 3 February 2026 – issue of shares on exercise of options | 7,903,778 | |
| **30 June 2026** | **705,103,778** | **703,662,758** |

On 25 June 2025, 194,600,000 ordinary shares of 0.02p were issued at 2.5p per share as part of a £4,865,000 (before expenses) fund raising. In addition, as part of the fundraising arrangements, the Company issued 2,600,000 ordinary shares at the issue price to advisors in lieu of advisory fees.

On 3 February 2026, 7,903,778 ordinary shares of 0.02p were issued at par following the exercise of options by former employees of the Company.

The calculation of loss per share is based on the following:

| | **Unaudited Six months ended 30 June 2026** | Unaudited Six months ended 30 June 2025 | Audited Year ended 31 December 2025 |
|---|---|---|---|
| Loss attributable to equity holders of the Company (£'000) | **(1,940)** | (2,178) | (5,695) |
| Weighted average number of ordinary shares in issue | **703,662,758** | 506,537,017 | 602,652,055 |
| Fully diluted average number of ordinary shares in issue | **703,662,758** | 506,537,017 | 602,652,055 |
| **Basic and diluted loss per share** | **(0.28)p** | (0.43)p | (0.94)p |

Under IAS 33.43 "Earnings per Share", the calculation of loss per share does not assume conversion, exercise, or other issue of potential shares that would have an antidilutive effect on LPS. For the current and comparative periods, the effect of options would be to reduce the loss per share and as such the basic and diluted LPS are the same.

***Share options and warrants in issue:***

| | **Share Options** | | **Warrants** | |
|---|---|---|---|---|
| | **Units** | **Weighted average exercise price** | **Units** | **Weighted average exercise price** |
| **31 December 2024 & 30 June 2025** | **64,247,419** | **7.5p** | **829,181** | **10.0p** |
| Lapsed during the period | (3,951,891) | 0.02p | — | — |
| **31 December 2025** | **60,295,528** | **8.0p** | **829,181** | **10.0p** |
| Exercised during the period | (7,903,778) | 0.02p | — | — |
| **30 June 2026** | **52,391,750** | **9.2p** | **829,181** | **10.0p** |

**4. Intangible assets**

| | **Acquired Licences & Data £'000** | **Patents & Trademarks £'000** | **Total £'000** |
|---|---|---|---|
| **Cost** | | | |
| At 31 December 2024 | **1,521** | **347** | **1,868** |
| Additions | **—** | 80 | **80** |
| Disposals | **—** | (8) | **(8)** |
| At 31 December 2025 | **1,521** | **419** | **1,940** |
| Additions | — | 54 | **54** |
| Disposals | — | (2) | **(2)** |
| **At 30 June 2026** | **1,521** | **471** | **1,992** |
| | | | |
| **Amortisation and impairment** | | | |
| At 31 December 2024 | **93** | **91** | **184** |
| Amortisation charge | 25 | 34 | **59** |
| Impairment charge | 26 | **—** | **26** |
| Disposals | **—** | (3) | **(3)** |
| At 31 December 2025 | **144** | **122** | **266** |
| Amortisation charge | 13 | 24 | **37** |
| Disposal | — | (1) | **(1)** |
| **At 30 June 2026** | **157** | **145** | **302** |
| | | | |
| **Net book value** | | | |
| **Net book value at 30 June 2026** | **1,364** | **326** | **1,690** |
| Net book value at 31 December 2025 | 1,377 | 297 | 1,674 |

**5 Trade and other receivables**

| | **Unaudited 30 June 2026 £'000** | Unaudited 30 June 2025 £'000 | Audited 31 December 2025 £'000 |
|---|---|---|---|
| Accounts receivables | **36** | 3 | 67 |
| Prepayments and accrued income | **202** | 395 | 265 |
| Grant receivable | **61** | 61 | 32 |
| VAT recoverable | **156** | 91 | 53 |
| R&D tax credit | **185** | 188 | 138 |
| **Trade and other receivables** | **640** | 738 | 555 |

**6. Events after the reporting period**

On 13 July 2026, Poolbeg announced the dosing of the first patient in the POLB 001 TOPICAL clinical trial.

On 14 July 2026, Poolbeg announced that it raised £3.5 million (before expenses) pursuant to a placing of 58,333,328 new ordinary shares of 0.02 pence each in the capital of the Company at an issue price of 6 pence per share with certain existing institutional and other investors. In connection with the placing the Company agreed to grant warrants to subscribe for 2,750,000 new ordinary shares at the placing issue price to Oak Securities, the sole bookrunner for the placing.

On 24 September 2026, Poolbeg announced that the ongoing POLB 001 TOPICAL clinical trial will proceed as planned following a positive review of data from the interim safety cohort. The review recommended that the trial continue as planned, with no changes required to the study protocol.

**7. Copy of the interim results**

A copy of the Company's Interim Results for the six months to 30 June 2026 is available on the Company's website, www.poolbegpharma.com/investors/documents/